share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%), etc.

Altimmune | SC 13G/A：超过5%持股股东披露文件(修正)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%)等

SEC announcement ·  02/14 11:37
Moomoo AI 已提取核心信息
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing was made by three investment management firms: Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all organized under the laws of Delaware. According to the amendment, NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares of Altimmune's common stock. Collectively, these firms now beneficially own 1,727,316 shares, representing 3.21% of the company's class of common stock. The filing, dated February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc.
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing was made by three investment management firms: Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all organized under the laws of Delaware. According to the amendment, NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares of Altimmune's common stock. Collectively, these firms now beneficially own 1,727,316 shares, representing 3.21% of the company's class of common stock. The filing, dated February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc.
2023年12月31日，生物制药公司Altimmune Inc. 成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，这表明重要投资者的所有权发生了变化。该文件由三家投资管理公司提交：Nuveen资产管理有限责任公司（NAM）、TIAA-CREF投资管理有限责任公司（TCIM）和Teachers Advisors, LLC（TAL），均根据特拉华州法律成立。根据该修正案，不结盟运动报告了6,679股股票的所有权，TCIM报告了1,549,364股股票，TAL报告了171,273股Altimmune普通股。这些公司现在共拥有1,727,316股股票，占公司普通股类别的3.21％。这份日期为2024年2月14日的文件称，这些股票是在正常业务过程中收购的，不是为了改变或影响Altimmune Inc.的控制权。
2023年12月31日，生物制药公司Altimmune Inc. 成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，这表明重要投资者的所有权发生了变化。该文件由三家投资管理公司提交：Nuveen资产管理有限责任公司（NAM）、TIAA-CREF投资管理有限责任公司（TCIM）和Teachers Advisors, LLC（TAL），均根据特拉华州法律成立。根据该修正案，不结盟运动报告了6,679股股票的所有权，TCIM报告了1,549,364股股票，TAL报告了171,273股Altimmune普通股。这些公司现在共拥有1,727,316股股票，占公司普通股类别的3.21％。这份日期为2024年2月14日的文件称，这些股票是在正常业务过程中收购的，不是为了改变或影响Altimmune Inc.的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息